BUSCADOR RECOLECTA

New French extreme cinema combines existentialism with shock, hyper violence, and transgressions of women’s bodies. I contend such imagery is best understood as a representation of violence that enables enlightenment in and through the representation of women’s monstrosity and abjection. I examine this phenomenon through four films from New French Extremism’s inaugural cycle. El Nuevo Extremismo Francés combina el existencialismo con el shock, la hiperviolencia y las transgresiones de los cuerpos de las mujeres. En este artículo argumento que dicho imaginario se entiende mejor como una representación de la violencia que permite acceder al conocimiento mediante la representación de la monstruosidad y el abyecto de la mujer. Examino este fenómeno a través de cuatro películas de la primera ola de dicho movimiento., New French extreme cinema combines existentialism with shock, hyper violence, and transgressions of women’s bodies. I contend such imagery is best understood as a representation of violence that enables enlightenment in and through the representation of women’s monstrosity and abjection. I examine this phenomenon through four films from New French Extremism’s inaugural cycle. El Nuevo Extremismo Francés combina el existencialismo con el shock, la hiperviolencia y las transgresiones de los cuerpos de las mujeres. En este artículo argumento que dicho imaginario se entiende mejor como una representación de la violencia que permite acceder al conocimiento mediante la representación de la monstruosidad y el abyecto de la mujer. Examino este fenómeno a través de cuatro películas de la primera ola de dicho movimiento.

INTRODUCTION: OHVIRA syndrome is a rare entity characterized by renal and Mullerian anomalies. The objective of the video is, through a clinical case, to discuss the importance of diagnosis, management and treatment, to avoid the complications that this syndrome entails, and to improve the long-term prognosis. MATERIALS AND METHODS: We report the case of a 10-year-old girl who consulted for abdominal pain, being diagnosed with OHVIRA syndrome. We describe the diagnosis and the surgical technique. In addition, we perform a systematic review in PubMed to report the published literature of this topic and we show the optimal management of this pathology.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations, Background COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but the severity of the condition prompted the use of several pharmacological and non-pharmacological interventions. It has long been hypothesized that the use of convalescent plasma (CP) from infected patients who have developed an effective immune response is likely to be an option for the treatment of patients with a variety of severe acute respiratory infections (SARI) of viral etiology. The aim of this study is to assess the efficacy and safety of convalescent plasma in adult patients with severe COVID-19 pneumonia. Methods/design The ConPlas-19 study is a multicenter, randomized, open-label controlled trial. The study has been planned to include 278 adult patients hospitalized with severe COVID-19 infection not requiring mechanical ventilation (invasive or non-invasive). Subjects are randomly assigned in a 1:1 ratio (139 per treatment arm), stratified by center, to receive intravenously administered CP (single infusion) plus SOC or SOC alone, and are to be followed for 30 days. The primary endpoint of the study is the proportion of patients that progress to category 5, 6, or 7 (on the 7-point ordinal scale proposed by the WHO) at day 15. Interim analyses for efficacy and/or futility will be conducted once 20%, 40%, and 60% of the planned sample size are enrolled and complete D15 assessment. Discussion This clinical trial is designed to evaluate the efficacy and safety of passive immunotherapy with convalescent plasma for the treatment of adult patients hospitalized with COVID-19. The results of this study are expected to contribute to establishing the potential place of CP in the therapeutics for a new viral disease. Trial registration ClinicalTrials.gov NCT04345523. Registered on 30 March, 2020. First posted date: April 14, 2020, This research is funded by the Government of Spain, Ministry of Science and Innovation, Instituto de Salud Carlos III, grant n° COV20/00072 (Royal Decree-Law 8/2020, of 17 March, on urgent extraordinary measures to deal with the economic and social impact of COVID-19), co-financed by the European Regional Development Fund (FEDER) “A way to make Europe,” and supported by SCReN (Spanish Clinical Research Network), ISCIII, project PT17/0017/0009. The funding institutions do not have any role in the design of the study, data collection, analysis, or interpretation of data, nor in writing the manuscript